Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Conditions
Brief summary
The objective of this study is to investigate the safety, tolerability and preliminary activity of ivosidenib in combination with durvalumab and gemcitabine/cisplatin as first-line therapy in participants with locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation. The study will begin with a safety lead-in phase (Phase 1b study) to determine the recommended combination dose (RDC) and then will transition to an expansion phase (Phase 2 study) to assess the clinical activity of ivosidenib in combination with durvalumab and gemcitabine/cisplatin at the RCD. During the treatment period participants will have study visits on days 1, 8, and 15 of Cycle 1, on days 1 and 8 of Cycle 2 to 8, and on day 1 of each additional cycle. Cycles 1 through 8 are 21 day cycles, and each following cycle is 28 days. Approximately 30 days and 90 days after treatment has ended, safety follow-up visits will occur and then participants will be followed for survival every 3 months. Study visits may include blood tests, ECG, vital signs, and a physical examination.
Interventions
DRUGIvosidenib
Two 250 mg tablets, totaling 500 mg, administered orally once daily, taken continuously throughout treatment duration
DRUGDurvalumab (for the first 8, 21-day, cycles)
1500mg intravenous (IV) infusion every 3 weeks, for a maximum of 8 (21-day) cycles
DRUGGemcitabine (for the first 8, 21-day, cycles)
1000 mg/m2 IV infusion on days 1 and 8 of every 21-day cycle, for a maximum of 8 cycles
DRUGCisplatin (for the first 8, 21-day, cycles)
25 mg/m\^2 IV infusion on days 1 and 8 of every 21-day cycle, for a maximum of 8 cycles
DRUGDurvalumab (starting from cycle 9)
1500mg intravenous (IV) infusion every 4 weeks, starting from cycle 9. Cycles are 28 days long, starting Cycle 9.
DRUGIvosidenib Recommended Combination Dose (RCD)
RCD administered orally once daily, taken continuously throughout treatment duration
Sponsors
Institut de Recherches Internationales Servier
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have a histopathological confirmed diagnosis consistent with locally advanced unresectable or metastatic cholangiocarcinoma. * Have documented IDH1 gene-mutated cholangiocarcinoma based on local or central laboratory testing (R132C/L/G/H/S mutation variants tested). * Have at least one evaluable and measurable lesion as defined by RECIST v1.1. * Have adequate bone marrow function as evidenced by: * Absolute neutrophil count ≥ 1,500/mm3 or 1.5 ×109/L * Hemoglobin ≥ 9 g/dL * Platelet count ≥ 100,000/mm3 or 100 × 109/L * Have adequate hepatic function as evidenced by: * Serum bilirubin ≤ 2.0 × the upper limit of normal (ULN); this will not apply to patients with confirmed Gilbert's syndrome. Any clinically significant biliary obstruction should be resolved before randomization * Aspartate aminotransferase (AST), and alanine aminotransferase (ALT) ≤ 2.5 × ULN; for patients with hepatic metastases, ALT and AST ≤ 5.0 × ULN * Have adequate renal function, defined as: creatinine clearance \> 60 mL/min per 24 hour urine or as calculated on the Cockcroft-Gault formula (using actual body weight): Creatine CL (mL/min)= (140 - Age) × (weight in kg) × (0.85 if female)/72 × serum creatinine (mg/dL)
Exclusion criteria
* Received treatment for locally advanced, unresectable or metastatic disease with the following exceptions: * Treatment with up to one cycle of durvalumab plus gemcitabine/cisplatin treatment is permitted before study participation. Note: For the Safety Lead-In Phase, participants who received one prior cycle of durvalumab plus gemcitabine/cisplatin and required dose modifications for treatment-related toxicity are excluded. * Patients who developed recurrent disease \> 6 months after surgery with curative intent, and, if given, \> 6 months after the completion of adjuvant (chemotherapy and/or radiation). * Prior exposure to immune-mediated therapy, including, but not limited to, anti-PD-1or other anti-PD-L1, and anti-PD-L2, anti-CTLA-4 antibodies, excluding therapeutic anticancer vaccines. * Unresolved Grade ≥2 adverse events from a previous anticancer therapy, with the exception of alopecia and vitiligo and the laboratory values listed in the inclusion criteria. * Patients with Grade ≥2 neuropathy to be evaluated on a case-by-case basis after consultation with the medical monitor * Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with ivosidenib may be included only after consultation with the medical monitor * Participation in another interventional study at the same time or within 14 days prior to the first study medication (triple combination treatment) administration. For patients having participated to another prior interventional study, the first dose of ivosidenib should occur after a period greater than or equal to 5 half-lives or 28 days, whichever is shorter of the last dose of the prior investigational product. * Active or prior documented autoimmune or inflammatory disorders including: * inflammatory bowel disease (e.g., colitis or Crohn's disease) * diverticulitis (with the exception of diverticulosis) * systemic lupus erythematosus * Sarcoidosis syndrome * Wegener syndrome (granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.) Note: in cases with no active disease for ≥ 5 years, patients may be considered for inclusion if approved by the Medical Monitor. Participants with the following conditions are eligible for the study: * chronic skin condition that does not require systemic therapy * vitiligo * alopecia * hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement therapy * unmedicated celiac disease that is controlled by diet * Have heart rate-corrected QT interval using Fridericia's formula (QTcF) of ≥ 450 msec or with other factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome/sudden death, polymorphic ventricular arrhythmia). The Sponsor should review participants with bundle branch block and prolonged QTcF for potential inclusion. * Have an active infection, including: * Hepatitis B (clinical evaluation includes: presence of hepatitis B surface antigen \[HBsAg\] and/or anti-HBcAb with detectable hepatitis B virus \[HBV\] DNA ≥ 10 IU/mL) * Hepatitis C * Tuberculosis (clinical evaluation includes: clinical history, physical examination and/or radiographic findings, and tuberculosis testing as per local practice) * Human immunodeficiency virus (clinical evaluation includes: positive HIV 1/2 antibodies) Note: Patients with a resolved or past HBV infection (i.e., presence of hepatitis B core antibody \[anti-HBc\] and absence of HBsAg) do not need to be excluded from the study. Patients positive for hepatitis C (HCV) antibody are eligible only if the polymerase chain reaction is negative for HCV RNA.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety Lead-in Phase: Number of Dose-limiting toxicities (DLTs) | Through Cycle 1 (Cycle 1 is 21 days) | — |
| Safety Lead-in Phase: Number of adverse events (AEs), adverse events of special interest (AESIs), and serious adverse events (SAEs) | Through 90 days after the end of treatment (Approximately 5 years) | — |
| Expansion Phase: Objective response rate (ORR) | Through the end of the study (Approximately 5 years) | Confirmed complete response (CR) or confirmed partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety Lead-in Phase: Ivosidenib Area under the concentration-versus-time curve (AUC) from time 0 to time of last measurable concentration (AUC0-t) | Through the end of treatment (Approximately 5 years) | — |
| Safety Lead-in Phase: Ivosidenib AUC over 1 dosing interval at steady state (AUCtau,ss) | Through the end of treatment (Approximately 5 years) | — |
| Safety Lead-in Phase: Ivosidenib time to maximum concentration (Tmax) | Through the end of treatment (Approximately 5 years) | — |
| Safety Lead-in Phase: Ivosidenib maximum concentration (Cmax) | Through the end of treatment (Approximately 5 years) | — |
| Safety Lead-in Phase: Ivosidenib trough concentration (Ctrough) | Through the end of treatment (Approximately 5 years) | — |
| Safety Lead-in Phase: Ivosidenib apparent volume of distribution (Vd/F) | Through the end of treatment (Approximately 5 years) | — |
| Safety Lead-in Phase: Ivosidenib apparent clearance (CL/F) | Through the end of treatment (Approximately 5 years) | — |
| Safety Lead-in Phase: Plasma 2-hydroxygluturate (2-HG) concentrations | Through the end of treatment (Approximately 5 years) | — |
| Expansion Phase: Number of AEs, AESIs, and SAEs | Through 90 days after the end of treatment (Approximately 5 years) | — |
| Expansion Phase: Overall survival (OS) | Through the end of the study (Approximately 5 years) | — |
| Expansion Phase: Duration of response (DOR) | Through the end of the study (Approximately 5 years) | — |
| Expansion Phase: Progression-free survival (PFS) | Through the end of the study (Approximately 5 years) | — |
| Expansion Phase: Disease control | Through the end of the study (Approximately 5 years) | Confirmed CR, confirmed PR, or stable disease \[SD\] |
| Expansion Phase: Time to response (TTR) | Through the end of the study (Approximately 5 years) | — |
| Expansion Phase: Ivosidenib Area under the concentration-versus-time curve (AUC) from time 0 to time of last measurable concentration (AUC0-t) | Through the end of treatment (Approximately 5 years) | — |
| Expansion Phase: Ivosidenib AUC over 1 dosing interval at steady state (AUCtau,ss) | Through the end of treatment (Approximately 5 years) | — |
| Expansion Phase: Ivosidenib time to maximum concentration (Tmax) | Through the end of treatment (Approximately 5 years) | — |
| Expansion Phase: Ivosidenib maximum concentration (Cmax) | Through the end of treatment (Approximately 5 years) | — |
| Expansion Phase: Ivosidenib trough concentration (Ctrough) | Through the end of treatment (Approximately 5 years) | — |
| Expansion Phase: Ivosidenib apparent volume of distribution (Vd/F) | Through the end of treatment (Approximately 5 years) | — |
| Expansion Phase: Ivosidenib apparent clearance (CL/F) | Through the end of treatment (Approximately 5 years) | — |
| Expansion Phase: Plasma 2-hydroxygluturate (2-HG) concentrations | Through the end of treatment (Approximately 5 years) | — |
Countries
Australia, Brazil, Canada, France, Germany, Japan, South Korea, Spain, United States
Contacts
CONTACTInstitut de Recherches Internationales Servier (I.R.I.S.) Clinical Studies Department
Outcome results
None listed